A new treatment holds the promise of possibly curing a debilitating disease that disproportionately affects the African American community, sickle cell disease. Researchers from UCSF, UC Berkeley, and UCLA are teaming up to defeat the disease by changing the patient's genetics. To do that, they've turned to a Nobel prize-winning gene-editing technology co-discovered by UC Berkeley biochemistry professor Jennifer Doudna. Known as CRISPR, the system allows doctors to identify genes that cause disease and then replace them with new DNA - a process known as gene editing. For more on this, see our press release at Berkeley News.